Meeting
2017 ASCO Annual Meeting
Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
Authors
Claud Grigg
Columbia University Medical Center, New York, NY
Claud Grigg , Brian D. Reuland , Adrian G. Sacher , Randy Yeh , Naiyer A. Rizvi , Catherine A. Shu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9082)
DOI
10.1200/JCO.2017.35.15_suppl.9082
Abstract #
9082
Poster Bd #
408
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
First Author: Christian Grohé
Poster
2019 ASCO Annual Meeting
Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.
First Author: Christian Grohé
Poster
2021 ASCO Annual Meeting
Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.
First Author: Alex K. Bryant
Poster
2019 ASCO Annual Meeting
Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).
First Author: Zofia Piotrowska